BPR1K653: A New Drug for Cancer Treatment
Author Information
Author(s): Cheung Chun Hei Antonio, Lin Wen-Hsing, Hsu John Tsu-An, Hour Tzyh-Chyuan, Yeh Teng-Kuang, Ko Shengkai, Lien Tzu-Wen, Coumar Mohane Selvaraj, Liu Jin-Fen, Lai Wen-Yang, Shiao Hui-Yi, Lee Tian-Ren, Hsieh Hsing-Pang, Chang Jang-Yang
Primary Institution: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan R.O.C.
Hypothesis
Can BPR1K653 effectively inhibit cancer cell growth regardless of MDR1 expression?
Conclusion
BPR1K653 is a potent anti-cancer compound that works effectively against both drug-sensitive and drug-resistant cancer cells.
Supporting Evidence
- BPR1K653 inhibited Aurora-A and Aurora-B kinase activity at low concentrations.
- It showed potent anti-proliferative activity against various cancer cell lines.
- BPR1K653 induced apoptosis in both MDR1-negative and MDR1-positive cancer cells.
- It effectively reduced tumor growth in xenograft models.
- BPR1K653's effectiveness was not affected by MDR1 expression.
- It exhibited favorable pharmacokinetic properties in rats.
- BPR1K653 was well-tolerated with minimal toxicity in animal models.
Takeaway
BPR1K653 is a new medicine that helps fight cancer, even in cases where other treatments don't work.
Methodology
The study involved in vitro and in vivo experiments to assess the effectiveness of BPR1K653 on various cancer cell lines and xenograft models.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website